Unlabelled: The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (biological DMARDs, or biologics) on the course and outcomes of a new coronavirus infection. A number of studies have shown that anti-B-cell therapy (rituximab) gave a statistically significant increase in the risk of severe COVID-19 and an increase in mortality.
View Article and Find Full Text PDFThe COVID-19 pandemic has brought significant changes in managing of patients with rheumatoid arthritis. Rituximab-treated patients were more susceptible to severe infection. This required a "switch" to another genetically engineered drug in the patients with high risk of adverse COVID-19.
View Article and Find Full Text PDFThe aim of the work is to study the nature of the distribution of 2-A-4.6-DNP in the organisms of warm-blooded animals with intragastric administration of a toxicant. The study was carried out using the methods of TLC, UV-Visible spectroscopy, and GC-MS using derivatives of 2-A-4.
View Article and Find Full Text PDFIs to study a 2, 4, 6-trinitrophenol (2.4,6-TNP) distribution in warm-blooded animals using physical chemical analysis methods after intragastric injection of toxicant. The methods of thin-layer chromatography, spectrophotometry and high-efficient liquid chromatography were used in the study process.
View Article and Find Full Text PDF